Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine

Vaccine

Volumn 32, Issue 49, 2014, Pages 6597-6600

  Hegerle, N ^a,b,c   Dore, G ^a,b   Guiso, N ^a,b  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bordetella pertussis; Mice colonization; Pertactin deficiency; Whooping cough

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; PERTACTIN; ACELLULAR VACCINE; BORDETELLA VIRULENCE FACTOR; OUTER MEMBRANE PROTEIN; PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; FEMALE; FITNESS; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BORDETELLOSIS; GENETICS; HETEROZYGOTE; IMMUNOLOGY; MICROBIOLOGY;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA INFECTIONS; BORDETELLA PERTUSSIS; CARRIER STATE; FEMALE; MICE, INBRED BALB C; MODELS, ANIMAL; PERTUSSIS VACCINE; VACCINES, ACELLULAR; VIRULENCE FACTORS, BORDETELLA;

EID: 84922667203     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.068     Document Type: Article

References (14)

1. Hegerle N., Guiso N. Epidemiology of whooping cough & typing of Bordetella pertussis. Future Microbiol 2013, 8:1391-1403.
2. Clark T.A. Changing pertussis epidemiology: everything old is new again. J Infect Dis 2014, 209:978-981.
3. Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011, 11:557-570.
4. Mastrantonio P., Spigaglia P., van Oirschot H., van der Heide H.G., Heuvelman K., Stefanelli P., et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 1999, 145(Pt 8):2069-2075.
5. Hegerle N., Guiso N. Bordetella pertussis and pertactin deficient clinical isolates: lessons for pertussis vaccines. Expert Rev Vaccine 2014, 13.
6. Bouchez V., Brun D., Cantinelli T., Dore G., Njamkepo E., Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 2009, 27:6034-6041.
7. Hegerle N., Paris A.S., Brun D., Dore G., Njamkepo E., Guillot S., et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis 2012, 18:E340-E346.
8. Hegerle N., Guiso N. Antibody-mediated inhibition of Bordetella pertussis adenylate-cyclase hemolysin-induced macrophage cytotoxicity is influenced by variations in the bacterial population. Microbiology 2014.
9. Morel S., Denoel P., Godfroid F., Cortvrindt C., Vanderheyde N., Poolman J. Induction of Bordetella pertussis-specific immune memory by DTPa vaccines. Vaccine 2011, 29:3449-3455.
10. Guiso N., Capiau C., Carletti G., Poolman J., Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 1999, 17:2366-2376.
11. Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis: Off Publ Infect Dis Soc Am 2009, 49:1565-1569.
12. Bodilis H., Guiso N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis 2013, 19:471-474.
13. Miyaji Y., Otsuka N., Toyoizumi-Ajisaka H., Shibayama K., Kamachi K. Genetic analysis of isolates from the 2008-2010 pertussis epidemic in Japan. PLOS ONE 2013, 8:e77165.
14. Advani A., Van der Heide H.G., Hallander H.O., Mooi F.R. Analysis of Swedish Bordetella pertussis isolates with three typing methods: characterization of an epidemic lineage. J Microbiol Methods 2009, 78:297-301.